Scientific Sessions
Scientific Sessions
  • Program
  • #AHA24
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Photo Gallery
  • Journeys
Resources
  • Program
  • #AHA24
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter X icon Facebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 12th, 2021

Session explores cancer and heart health links


Olympian gold-medal winner and cancer survivor Kikkan Randall and Saro Armenian, DO, MPH
Olympian gold-medal winner and cancer survivor Kikkan Randall and Saro Armenian, DO, MPH

What can an Olympic champion skier teach us about the connections between cancer and heart health? If that champion is five-time Olympian, gold-medal winner and cancer survivor Kikkan Randall, the answer is plenty.

Randall will talk about her experience during “Cardio-Oncology: From a Science Journey to a Patient Journey” 9:30-10:30 a.m. EST, Saturday. She was diagnosed with cancer just four months after winning an Olympic gold medal in the cross-country skiing team sprint event.

As a lifelong athlete, Randall said she was concerned about how her cancer treatments might affect her heart and was committed to doing everything she could to support good heart health.

Randall said her presentation will focus on the importance of exercising whenever possible during cancer treatment. 

“Exercise is a key part of helping cancer treatment be as successful as possible,” she said. “For as much as it helped me physically, the exercise really helped my mental state through one of the toughest times in my life. If I exercised — even a short amount — I could tell I was able to stay more positive and optimistic and stay focused on keeping healthy habits like diet, sleep and hydration going every day to support my training.”

Stressing the importance of exercise is a critical message for both doctors and patients alike, according to Randall.

She further emphasized, "A doctor is like a coach — they have tremendous influence on how the patients view physical activity during treatment. If physicians are advocating for their patients to stay active, I believe that will get more patients to see that daily activity is as integral to their treatment as the other therapies.”

Saro Armenian, DO, MPH, a pediatric hematologist in Duarte, California, will offer another perspective on heart health and cancer survival in her presentation, “From Birth to Life — The Heart Journey of Cancer Survivorship.”

Dr. Armenian said there is a strong connection between heart health and cancer survivorship.

“Cardiovascular disease is a leading cause of non-cancer related morbidity in cancer survivors,” he said. “The risk for CVD in cancer survivors is multifaceted.”

“I hope attendees will come to understand the relative risk of CVD in cancer survivors compared to the general population,” he said. “I also want them to be able to understand the specific cancer treatments associated with CVD during and after completion of cancer treatment and recognize the high-risk subgroups for surveillance and intervention to mitigate CVD risk.” 

Dr. Armenian said there is still much to be learned about the connection between cancer treatments and cardiovascular disease. 

“It is increasingly recognized that cancer and its treatments may contribute to accelerated cardiovascular aging in certain high-risk populations,” he said. “The biology of accelerated cardiovascular aging is not fully elucidated. There are a number of bench-to-bedside studies examining the pathology of CVD in the context of cancer.”

Dr. Armenian hopes to draw a line between cancer survivors and an increased risk of cardiovascular disease.

Editor's Note

This AHA scientific statement has just been released and summarizes the current literature on the use of established cardiovascular biomarkers at the intersection with cancer and identifies limitations and gaps regarding the use of biomarkers to stratify CV risk prior to cancer treatment, monitor CV health during therapy and detect latent CV damage in survivors.

Future Perspectives of Cardiovascular Biomarker Utilization in Cancer Survivors: A Scientific Statement From the American Heart Association 

Visit Scientific Sessions Conference Coverage for more articles.

 


 

 

Interesting Stories
Lp(a) and Peripheral Artery Disease Toolkit
Sponsored by Kaneka Corporation
Lp(a) and Peripheral Artery Disease Toolkit
Screening for Kidney Disease to Reduce CVD Risk
Sponsored by Bayer
Screening for Kidney Disease to Reduce CVD Risk
Unmet Needs in Hypertension Toolkit
Sponsored by Medtronic
Unmet Needs in Hypertension Toolkit
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
Sponsored by Medscape
CME Gameshow Style Sympo: Navigating New Paradigms in Thrombosis Management
More Content
Getty Images 1180201381
Daily Coverage
Join the Scientific Sessions 2022 Scavenger Hunt
Aug 15th, 2022
Live Meeting Image
AHA21
Member Connect
Dec 13th, 2021
P104 Steven Botts Image
AHA21
Members Connect: ERG Governs Chromatin Accessibility in Aortic Endothelial Cells
Dec 13th, 2021
Pres Address Lloyd Jones2
AHA21
Watch: #AHA21 recap and look ahead
Nov 22nd, 2021
Getty Images 1301907602
AHA21
Mark your calendar for #AHA22
Nov 19th, 2021
Elaine Hylek, MD, MPH, and Bruno Caramelli, MD, PhD
AHA21
Trials’ results suggest advancements in treatment approaches for AF and insight on the cardiac effects of coffee consumption
Nov 19th, 2021
Lbs02 Group Blood Patel
AHA21
Update on local and global hypertension science
Nov 19th, 2021
Getty Images 1219980553 61849bc953192
AHA21
Read all about #AHA21 in your daily coverage
Nov 16th, 2021
(from left to right): Brahmajee K. Nallamothu, MD, MPH, FAHA, Rhoda Au, PhD, Seth Martin, MD, MHS, FAHA, and Andrea Beaton, MD, FAHA
AHA21
QCOR at Sessions: mHealth strategies could help treat CVD around the world
Nov 15th, 2021
(from left to right, top to bottom rows): Corey E. Ventetuolo, MD, MS, Magdi Yacoub, OM, FRS, Karen Joynt Maddox, MD, MPH, FAHA, Gregory Lewis, MD, Marco Guazzi, MD, PhD, FAHA, Ana Macumbi, MD, PhD, FESC, Mark T. Gladwin, MD, FAHA, and William Bain, MD
AHA21
The shifting profile of cardiopulmonary COVID-19 survivors
Nov 15th, 2021
(from left to right): Jonathan P. Piccini, MD, MHS, FAHA, and Steven A. Lubitz, MD, MPH, FAHA
AHA21
Late-Breaking Science: New information in cardiac disease
Nov 15th, 2021
(from left to right): Nasrien E. Ibrahim, MD, Stefan D. Anker, MD, PhD, and Clyde W. Yancy, MD, MSc, FAHA
AHA21
The latest science in heart failure
Nov 15th, 2021